CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.1% – Here’s What Happened

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report) shares were down 0.1% on Tuesday . The company traded as low as $40.94 and last traded at $41.80. Approximately 447,191 shares were traded during trading, a decline of 77% from the average daily volume of 1,968,914 shares. The stock had previously closed at $41.85.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays reduced their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Finally, JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $78.38.

Get Our Latest Research Report on CRSP

CRISPR Therapeutics Stock Up 2.0 %

The stock has a fifty day simple moving average of $43.88 and a 200-day simple moving average of $47.38. The company has a market capitalization of $3.59 billion, a P/E ratio of -14.86 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter last year, the business posted ($1.41) earnings per share. Analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its position in CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after acquiring an additional 211 shares during the period. Boston Family Office LLC grew its position in shares of CRISPR Therapeutics by 2.2% during the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC boosted its position in shares of CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after acquiring an additional 218 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of CRISPR Therapeutics by 1.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after buying an additional 231 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its position in shares of CRISPR Therapeutics by 11.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock valued at $139,000 after buying an additional 300 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.